Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Cowen & Company Healthcare Conference 2010
22 slides from Teva Pharmaceutical Industries's conference presentation, Mar 8, 2010
Slide 1: Cowen & Company Healthcare Conference
1 Cowen & Company Healthcare Conference Itzhak Krinsky, Ph.D, Corporate VP – Business Development March 8, 2010
Slide 2: Forward looking statements
Forward looking statements 2 TODAY’S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, INCLUDING, AMONG OTHER THINGS, REGARDING OUR EXPECTED PROFITABLE GROWTH, REVENUES, NET INCOME, THE DRIVERS AND CONTRIBUTORS OF THIS GROWTH, STRATEGY AND COMPETITIVE ADVANTAGES, WHICH EXPRESS THE CURRENT BELIEFS AN
Slide 3: 2009 Highlights / 2015 Strategy Update
3 2009 HIGHLIGHTS 2015 STRATEGY UPDATE
Slide 4: 2 fundamental questions/topics
2 fundamental questions/topics 4 2009 HIGHLIGHTS 2015 STRATEGY UPDATE
Slide 5: 2009 – strong results
2009 – strong results 5 2008* 2009* Change Sales 11,085 13,899 +25% $m Operating income 2,856 3,853 +35% $m Net income 2,493 3,029 +22% $m EPS 3.03 3.37 +11% $ Cash flow from operations 3,231 3,373 +4% $m * Net income, operating income and EPS are non GAAP results
Slide 6: 2009 – an extraordinary year
2009 – an extraordinary year 6 Record Record sales Financial Record profit levels: gross, operating and net Results Balance Record sales year 2008: an extraordinary in all geographies Business Record sales in all business lines Model Enhancing Copaxone® – solidify position as #1 MS treatment Branded
Slide 7: Excellent margins
Excellent margins 7 2008* 2009* Change Sales 11,085 13,899 +25% $m Operating income 2,856 3,853 +35% $m Net income 2,493 3,029 +22% $m Gross margin 55.3 58.4 % Operating margin 25.8 27.7 % Net margin 22.1 21.8 % * Operating income, net income, gross margin, operating market and net margin are non GA
Slide 8: 2009 – balanced business model
2009 – balanced business model 8 By business line By geography $13.9bn $13.9bn International Branded Europe Generic North America
Slide 9: 2010 guidance
2010 guidance 9 Net sales around $16 billion Non-GAAP EPS between $4.40 – $4.60 Significant variance between Q1’2010 and rest of year
Slide 10: 2 Fundamental questions/topics
2 Fundamental questions/topics 10 2009 HIGHLIGHTS 2015 STRATEGY UPDATE
Slide 11: Targets for 2015
Targets for 2015 11 Revenues $31 bn Net income $6.8 bn Net profitability 22%
Slide 12: Maintaining Teva's mix of generics & branded
Maintaining Teva’s mix of generics & branded 12 $31bn ~30% $13.9bn Branded 30% ~70% Generics 70% 2009 2015
Slide 13: Growth through market share
Growth through market share 13 2015 sales 2009-2015 targets CAGR North America $15bn 9.5% Europe $9bn 18.6% International $7bn 23.2% Total $31bn 14.3%
Slide 14: Is there still room to grow in generics? YES!
Is there still room to grow in generics? YES! 14 $135-150 bn in 2015 GROWTH GROWTH GROWTH GROWTH Increasing People living Healthcare $150bn of opportunities longer and reforms and brands going in emerging consuming cost saving off-patent generics more drugs initiatives in the next markets 5 years
Slide 15: Growing demand for generics
Growing demand for generics 15 Market outlook for global generic sales Source: Exane BNP Paribas, IMS, Espicom, Teva estimates
Slide 16: Governments playing a greater role
Governments playing a greater role 16 Focus on quality US healthcare Increased reform access Higher volume (outpacing potential Initiatives in many Increased pricing pressure) EU/international pace of markets Gx penetration
Slide 17: Strong International market growth
Strong International market growth 17 Pharma Market (CAGRs 2009-2015) CIS: Eastern 14% Europe: 10% Asia: Japan: 16% 3% Latin America: 12% International markets: 2009 : $ 241bn 2015: $ 473bn Source: 2009 – 2013 IMS Market Prognosis – Constant fx, Teva
Slide 18: Teva continues to focus on high priority markets
Teva continues to focus on high priority markets 18 ~75% of growth Priority Growth Markets 8 countries Established 52 countries Growth Markets
Slide 19: The Teva Advantage crosses all models
The Teva Advantage crosses all models 19 Multiple Generic Models Teva’s Advantage GGx • >1,000 molecules • Local market knowledge • Government Hospitals relationships BGx • Speed and agility • High quality products Tenders • Low cost manufacturing
Slide 20: Biosimilars: the future
Biosimilars: the future 20 2008 worldwide sales of biologics, $bn Strategic Alliances 23 115 Lonza 39 76 14 Teva’s Bio infrastructure Sicor, IBR&D, Patents Patents Patents Biosimilar Biosimilar CoGenesys expired expiring expiring opportunity - opportunity - before 2010 2010-2015 2016-2020 2008 brand
Slide 21: Teva 2010-2015: value creation
Teva 2010-2015: value creation 21 9 Growth 9 High profitability Sustainable, 9 balanced business model 9 Financial strength
Slide 22: Teva Pharmaceutical Industries Ltd
tA TEVA PHARMACEUTICAL INDUSTRIES LTD,
Teva Pharmaceutical Industries — Cowen & Company Healthcare Conference 2010 on 6ix